

iShares Healthcare Innovation UCITS ETF USD (Acc)

December Factsheet

Performance, Portfolio Breakdowns, Net Asset information as at: 31-Dec-2023

All other data as at: 05-Jan-2024

The Fund seeks to track the performance of an index composed of developed and emerging market companies which are generating significant revenues from specific sectors focused on pushing the boundaries in medical treatment and technology

KEY BENEFITS

- 1 Competitively priced and diversified access to companies across the world that are focused on innovation within global healthcare services, across both developed and emerging markets.
- 2 Growth potential due to major structural drivers including shifting global demographics, social changes and the increased application of technology.
- 3 Express a long-term view within your equity allocation through an ETF tracking an ESG-screened index (screened for Controversial Weapons, Weapons, Tobacco, Nuclear Power, Thermal Coal, Oil & Gas, and companies involved in severe ESG controversies).


KEY RISKS: Shares in smaller companies typically trade in less volume and experience greater price variations than larger companies. Emerging markets are generally more sensitive to economic and political conditions than developed markets. Other factors include greater 'Liquidity Risk', restrictions on investment or transfer of assets and failed/delayed delivery of securities or payments to the Fund.

(Continued on page 2)

GROWTH OF HYPOTHETICAL 10,000 USD SINCE INCEPTION



Calendar Year Returns



The figures shown relate to past performance. Past performance is not a reliable indicator of future results and should not be the sole factor of consideration when selecting a product or strategy. Share Class and Benchmark performance displayed in USD, hedged fund benchmark performance is displayed in USD. Performance is shown on a Net Asset Value (NAV) basis, with gross income reinvested where applicable. Performance data is based on the net asset value (NAV) of the ETF which may not be the same as the market price of the ETF. Individual shareholders may realize returns that are different to the NAV performance. The return of your investment may increase or decrease as a result of currency fluctuations if your investment is made in a currency other than that used in the past performance calculation. **Source:** BlackRock

CAPITAL AT RISK: The value of investments and the income from them can fall as well as rise and are not guaranteed. Investors may not get back the amount originally invested.

KEY FACTS

Asset Class	Equity
Fund Base Currency	USD
Share Class Currency	USD
Fund Launch Date	08-Sep-2016
Share Class Launch Date	08-Sep-2016
Benchmark	STOXX Global Breakthrough Healthcare Index
ISIN	IE00BYZK4776
Total Expense Ratio	0.40%
Distribution Type	Accumulating
Domicile	Ireland
Methodology	Optimised
Product Structure	Physical
Rebalance Frequency	Annual
UCITS	Yes
Use of Income	Accumulating
Management Company	iShares IV plc

Net Assets of Fund	USD 1,130,224,634
Net Assets of Share Class	USD 1,130,224,634
Number of Holdings	200
Shares Outstanding	151,000,000
Benchmark Ticker	IXBRHLTU
Fund Type	UCITS

TOP HOLDINGS (%)

NEUROCRINE BIOSCIENCES INC	1.84
AMGEN INC	1.73
KARUNA THERAPEUTICS INC	1.70
CELLTRION INC	1.60
AGILENT TECHNOLOGIES INC	1.60
CHARLES RIVER LABORATORIES	
INTERNA	1.54
BOSTON SCIENTIFIC CORP	1.50
ABBVIE INC	1.49
IQVIA HOLDINGS INC	1.48
REPLIGEN CORP	1.45
	15.93


Holdings are subject to change.

Key Risks Continued: Investment risk is concentrated in specific sectors, countries, currencies or companies. This means the Fund is more sensitive to any localised economic, market, political or regulatory events. The value of equities and equity-related securities can be affected by daily stock market movements. Other influential factors include political, economic news, company earnings and significant corporate events. Liquidity Risk: Lower liquidity means there are insufficient buyers or sellers to allow the Fund to sell or buy investments readily. Counterparty Risk: The insolvency of any institutions providing services such as safekeeping of assets or acting as counterparty to derivatives or other instruments, may expose the Fund to financial loss.

SECTOR BREAKDOWN (%)	
	Fund
Health Care	97.79
Information Technology	1.18
Industrials	0.85
Cash and/or Derivatives	0.18

PORTFOLIO CHARACTERISTICS	
Price to Earnings (TTM) Ratio	21.62x
Price to Book Ratio	3.79x

DEALING INFORMATION	
Exchange	London Stock Exchange
Ticker	HEAL
Bloomberg Ticker	HEAL LN
RIC	HEAL.L
SEDOL	BYZK477
Trading Currency	USD
This product is also listed on: Xetra,Tel Aviv Stock Exchange,Euronext Amsterdam,Bolsa Mexicana De Valores,Santiago Stock Exchange,Borsa Italiana,SIX Swiss Exchange	



GLOSSARY

Total Expense Ratio (TER): A measure of the total costs associated with managing and operating a fund. The TER consists primarily of the management fee plus other expenses such as trustee, custody, or operating expenses. It is expressed as a percentage of the fund's total net asset value.

Distribution yield: The distribution yield represents the ratio of distributed income over the last 12 months to the fund's current Net Asset Value.

Product Structure: Indicates whether the fund buys the actual underlying securities in the index (i.e. Physical) or whether the fund gains exposure to those securities by buying derivatives, such as swaps (known as 'Synthetic'). Swaps are a form of contract that promises to provide the return of the security to the fund, but the fund does not hold the actual security. This can introduce a risk that the counterparty defaults on the "promise" or contract.

Methodology: Indicates whether the product is holding all index securities in the same weight as the index (replicating) or whether an optimized subset of index securities is used (optimized/sampled) in order to efficiently track index performance.

Want to learn more?  latamiberia@blackrock.com

 www.blackrock.com/latamiberia

IMPORTANT INFORMATION:

BlackRock Advisors (UK) Limited, which is authorized and regulated by the Financial Conduct Authority ('FCA'), registered office at 12 Throgmorton Avenue, London, EC2N 2DL. Tel: +44 (0) 20 7743 3000. For your protection, calls are usually recorded. iShares plc, iShares II plc, iShares III plc, iShares IV plc, iShares V plc, iShares VI plc and iShares VII plc (together 'the Companies') are open-ended investment companies with variable capital having segregated liability between their funds organized under the laws of Ireland and authorized by the Central Bank of Ireland.

Capital at risk. The value of investments and the income from them can fall as well as rise and are not guaranteed. Investors may not get back the amount originally invested. Past performance is not a reliable indicator of current or future results and should not be the sole factor of consideration when selecting a product or strategy. Changes in the rates of exchange between currencies may cause the value of investments to diminish or increase. Fluctuation may be particularly marked in the case of a higher volatility fund and the value of an investment may fall suddenly and substantially. Levels and basis of taxation may change from time to time. BlackRock has not considered the suitability of this investment against your individual needs and risk tolerance. The data displayed provides summary information. Investment should be made on the basis of the relevant Prospectus which is available from the manager. In respect of the products mentioned this document is intended for information purposes only and does not constitute investment advice or an offer to sell or a solicitation of an offer to buy the securities described within. This document may not be distributed without authorisation from BlackRock.

This material has been produced by BlackRock® for educational purposes only and does not constitute investment advice, or an offer or solicitation to sell or a solicitation of an offer to buy any shares of any iShares ETFs (nor shall any such shares be offered or sold to any person) in any jurisdiction in which an offer, solicitation, purchase or sale would be unlawful under the securities laws of that jurisdiction. Most of the protections provided by the UK regulatory system do not apply to the operation of the Companies, and compensation will not be available under the UK Financial Services Compensation Scheme on its default. The Companies are recognized schemes for the purposes of the Financial Services and Markets Act 2000.

Before investing, you should consider the investment objectives, charges and expenses and the variety of risks (in addition to those described in the risk sections) of any applicable issuance documents.

In respect of the products mentioned this document is intended for information purposes only and does not constitute investment advice or an offer to sell or a solicitation of an offer to buy the securities described within. This document may not be distributed without authorisation from the manager.

© 2024 BlackRock, Inc. All Rights reserved. BLACKROCK, BLACKROCK SOLUTIONS, iSHARES, BUILD ON BLACKROCK, SO WHAT DO I DO WITH MY MONEY are registered and unregistered trademarks of BlackRock, Inc. or its subsidiaries in the United States and elsewhere. All other trademarks are those of their respective owners. © Morningstar. All Rights Reserved. The information, data, analyses, and opinions contained herein (1) include the proprietary information of Morningstar, (2) may not be copied or redistributed, (3) do not constitute investment advice offered by Morningstar, (4) are provided solely for informational purposes and therefore are not an offer to buy or sell a security, and (5) are not warranted to be correct, complete, or accurate. Morningstar shall not be responsible for any trading decisions, damages, or other losses resulting from, or related to, this information, data, analyses, or opinions or their use. LA-0544